With the development of SC injection devices, the paradigm of drug product development has continued to shift towards patient centricity by enabling self-administration and ease of use for patients, improving compliance and adherence and reducing the burden on healthcare systems.1 The number of approved monoclonal antibody (mAb) products has been increasing over the last few decades, with a proportional increase in the number of SC products (Figure 1), based on the information compiled by ten23 health on US FDA-approved products
10.1172/jci.insight.145632 38 NagashimaT.ShirakawaH.NakagawaT.KanekoS
Serious reactions, including allergic responses, are rare
| Frequently asked questions | Take home message Yes, you can take Wegovy (semaglutide) with metformin
Escalating Specialty Drug and GLP-1 Costs And the Strategies to Fight Them in 2025 and Beyond Managing pharmacy drug benefits is complex and high-touch
We offer a variety of weight loss treatments and tailor each plan to your unique goals